The International Council on Infertility Information Dissemination, Inc

Embryo Adoption

It is actually estimated that there are well over 100,000 frozen embryos in storage in the United States alone. And, with the recent advances in Assisted Reproductive Technologies (ART) and improved cryopreservation techniques, this technology has led to the wider use of frozen embryos for both donation and research. With that in mind, embryo donation still remains a comparatively new possibility that is just gaining ground as another viable option for those individuals and couples who have been desperately wishing for a child. In fact, it is often the only remaining viable alternative for those who have already been on the rollercoaster of infertility for many years and who have already invested significant amounts of time and money into their journey.

Although the number of available embryos may seem high, the actual number of embryos available to couples and individuals is really much lower since it is often a difficult decision to donate leftover embryos to someone else. In fact, many couples choose to destroy their remaining embryos or maintain them in the frozen state indefinitely since they are not willing to be contacted by any resulting child. On the other hand, the major motivations for the donation of one’s embryos are usually to give the embryo a chance at life or to allow other infertile couples to have a child.

What the ideal solution for any person is, whether to thaw and destroy, donate to stem cell research or donate to another person, may be the biggest decision faced by those with embryos in storage - in fact, it is a decision that is highly ethical, morally, and emotionally charged. For example, full siblings may never know one another, and there is the issue of contacting genetic siblings and parents in the event of health and medical issues.

Legally, it is also often confusing since one school of thought believes it to be an adoption while others a donation - with those choosing adoption seeing the embryos as children awaiting their destiny. Whatever way you choose to view this possibility - every donor must certainly consider the following possibilities when making your decision: a.) whether you will want the embryos for future siblings for any of your existing children; b.) how you feel about the real possibility that there may be other children alive who are the result of your own genetic material or that of your partner and a donor; and, c.) the pain of not knowing the result of your donation. Once a couple has decided to donate their embryos, there is one additional legal issue that cannot be disregarded; this issue revolves around the agreement between the donor parents of the embryos and any egg or sperm donor that was involved in the creation of these embryos. Specifically, if an egg donor or sperm donor agreement is in place that spells out the donor parents cannot donate these embryos to another couple without his or her consent, then this must absolutely be followed in order to protect the rights of the recipient parents.

It would be a tragedy to the recipient parents to have to deal with any litigation that may result if an egg donor discovered that the embryos from her donation were donated to another couple without

her consent. Although the rights of the egg donor have already been terminated, this sort of dispute can be a very scary discovery for a recipient couple that has already given birth to their resulting child. On the other hand, the options that are available to recipient couples and individuals are very few and far between once it has been determined that they need to move onto donor embryos. For example, you can sign up with a doctor’s office that has a lengthy waiting list for available embryos, or you can contact an adoption agency such as the SnowFlakes Embryo Adoption Program, whereby the participants are required to follow the same requirements that exist for traditional adoption. The other options are to locate embryos independently online (which is absolutely not recommended without some guidance from a physician, lawyer or psychologist) or to sign up with a non-profit agency, such as Embryo Options, which provides the parties the option to tailor their arrangement to their own needs and desires, such as whether to have a relationship

with the other party that is open, semi-anonymous or totally anonymous. Each of these programs is different in many aspects, and it is really a personal choice of any recipient couple or individual to choose the program that best fits their needs, whether religious, financial or otherwise.

In fact, once a couple or individual has reviewed the available programs, they need to be certain of a number of things before making a decision:

1.) Be aware of all financial requirements that are involved with these embryos, including but not limited to medications and clinic fees, if any, and whether the donors are requesting any fees in return;

2.) Ask questions about the program’s own guidelines and protocol;

3.) Ask the program how donor parents and recipient parents are selected and matched. Discover if the parties have the option to turn down embryos that have been offered to them or not;

4.) Ensure that the recipients and their doctors are entitled to the embryo quality reports, the (redacted) medical records of the donors and the results of any successful pregnancies.


Yet, no matter if you are a donor or a recipient, the parties must follow a protocol that protects everyone, to include any resulting children. In fact, the parties must sign legal consents, have a counseling session with a psychologist or social worker, and undergo infectious disease screening. The purpose of counseling is to discuss issues such as disclosure to the child at an appropriate age - both for medical and social reasons. From a legal standpoint, the legal system, nor the states’ legislatures, have clarified the actual donation of embryos from one couple to another. However, the case of Davis v. Davis (Tenn. 1992), as well as several others, have essentially given embryos the status of property when a dispute over the embryos arises out of a marital dissolution action. The

courts chose to decide against “forced procreation,” instead of providing the embryos with a higher (protected) status due to their ability to become life. In an effort to clarify the status of the embryos from the standpoint of donation, attorneys in this field have chosen to use this same argument to treat the embryos as the donation of genetic material, or property in a sense, from one couple to another much like egg donation.

Essentially, the lessons learned over the last decade have shown those attorneys practicing in this field that precise contract drafting is absolutely essential - your attorney must carefully scrutinize the contract terms since there are strong dicta favoring enforceability. Furthermore, the reimbursement of costs that may be requested by a donating couple must be considered very carefully before agreed upon by a recipient couple. Certainly, any additional medical testing required by the recipients’ clinic, as well as any outstanding storage fees, are acceptable fees to be paid; however, anything additional can make the donation itself questionable. To be sure, the donation of embryos does not involve the same sort of pain and suffering associated with the donation of eggs; therefore, it is best to stay away from any additional reimbursements that can be construed as the purchase and/or sale of embryos.

Finally, the success rates from the transfer of frozen embryos is certainly lower than that of a fresh embryo transfer, as is reported by the American Society for Reproductive Medicine (ASRM); however, the availability of this option of donor embryos is certainly one that should be considered by everyone, donors and recipients alike. To donors, it is the chance to help others and provide life to their frozen embryos; while, to recipients, it is a viable alternative in their journey to creating

their families - just remember to ensure that all parties, to include the resulting children, are protected.

*The information in this article is not, nor is it intended to be, legal advice. You should consult an attorney for individual advice regarding your own situation.




New York Becomes Tenth State to Require Coverage of IVF and Sixth State to Require Coverage for Fertility Preservation for Certain Patients

A map of New York State emphasizing the New Mandate insurance companies to cover IVF treatment

Apr 01, 2019 
Origin: ASRM Bulletin Vol.22 No.1 

ASRM Bulletin Volume 22 Number 1

April 1, 2019 

New York lawmakers passed a budget measure late yesterday which updates the state’s existing infertility statute to include a requirement for health plans operating in the large group market (employers with 100 or more full-time staff) to provide coverage for three cycles of in-vitro fertilization. The budget measure also includes a provision requiring that patients at risk for iatrogenic infertility
be covered for fertility preservation services. 

Passage of the budget measure with these provisions caps a multi-year effort
on the part of ASRM and coalition partners including RESOLVE, the Alliance for Fertility Preservation, EMD Serono and Ferring Pharmaceuticals to pass the Fair Access to Fertility Treatment Act.  Inclusion of major pieces of FAFTA in the budget measure is a major victory for patients in New York and brings the state in line with current medical standards of care.

Provisions to lift the existing ban on surrogacy in the state were not included in the budget measure despite the hard work of other coalition partners. ASRM will continue to seek passage of The Child Parent Security Act via the regular legislative process. 

ASRM issued the following press release.

Washington, DC - The American Society for Reproductive Medicine (ASRM) applauds the news that New York has passed a long overdue update to the state’s infertility statute as part of its budget bill today.

“We are ecstatic that the leaders in New York have voted to require insurance companies who
participate in the large group market in the state to provide infertility coverage, including IVF and fertility preservation. This measure will allow many New Yorkers to get the health care treatment they need
in order to build their families. New York’s reproductive medical professionals wish to express our gratitude to Governor Cuomo and his staff for their leadership and to the champions in the legislature, Assemblywoman Aravella Simotas and Sen. Diane Savino, who have made access to this care a priority for New York families,” stated Peter Schlegel MD, President of the American Society for Reproductive Medicine.

Dr. Schlegel
went on to add, “We
are not done in New York yet, however. Having passed this vital measure to improve access to IVF treatments, we call on the leaders of the legislature to follow the Governor’s lead and reform New York’s antiquated laws pertaining to surrogacy, another vital therapeutic option for patients.”


The ASRM Bulletin
is published by ASRM's Office of Public Affairs to inform Society members of important recent developments.
Republication or any other use of the contents of the Bulletin without permission is prohibited. To request permission to quote or excerpt material from the Bulletin, contact Sean Tipton at   



Sean Tipton 
Ph: 202-863-2494 

Eleanor Nicoll 
Ph: 202-863-2349 or 240-274-2209 (mobile) 

SRM Responds to News of Birth Following Successful Uterus Transplant

Dec 04, 2017 
Origin: ASRM Press Release 

ASRM issued the following press release today.

Statement attributable to Christos Coutifaris, MD, Ph.D., President of the American Society for Reproductive Medicine.

Washington, DC- This birth represents another important milestone in the history of reproductive medicine. 

Uterine factor infertility is estimated to affect 1 in 500 women of reproductive age and can result from either congenital absence of a uterus  or from a nonfunctional or surgically absent uterus. For these women, uterus transplantation represents the only way they can carry a pregnancy. In addition to the medical indications, uterus transplantation presents an important option for those living in jurisdictions where the use of gestational carriers is restricted, or whose own personal views and beliefs lead them to favor a uterus transplant.

ASRM supports further development of uterus transplantation as a therapeutic option and wishes to emphasize the need to move forward with caution and appropriate preparation. Work in this area should take place only under the oversight of an Institutional Review Board, and only in centers that can gather a strong multidisciplinary team, including a Reproductive Endocrinologist. Such centers should also have the resources for the in-depth training and preparation required to perform this very specialized procedure and take care of these patients.

ASRM is in the process of assembling a team of experts to develop a comprehensive guidance document that will allow potential programs the ability to understand the requirements for establishing this service and to assess the resources needed for considering this option. As with all our patients seeking to build their families, it is important to understand the full array of options available to them, including adoption, gestational carriers, and child-free living.


For more information on these press releases, contact: 

J. Benjamin Younger Office of Public Affairs 
409 12th Street SW, Suite 602 
Washington, DC 20024-2188
Tel: (202) 863-2494/Fax: (202) 484-4039


Eleanor Nicoll 
Ph: 202-863-2349 or 240-274-2209 (mobile) 

Sean Tipton 
Ph: 202-863-2494 

Ontario Leads Provinces in Helping Canadians Grow Their Families

Conceivable Dreams (CNW Group/Conceivable Dreams)

Conceivable Dreams releases 2016 provincial rankings on IVF access

TORONTO, May 11, 2016 /CNW/ - Ontario leads among the provinces in Canada when it comes to providing access and support to families and individuals struggling with infertility, a new ranking of provincial jurisdictions found.

The 2016 rankings, released by infertility patient group Conceivable Dreams in advance of Canadian Infertility Awareness Week, credited both Ontario's decision to begin funding one cycle of in vitro fertilization (IVF) and the choice of fertility clinics in the province with its top spot in the rankings.

"It was great to see Ontario deliver for those struggling with infertility," said Danielle Xavier, President, Conceivable Dreams. "Without question, Ontario now leads the country in helping patients who are struggling with infertility to grow their families through assisted reproductive technologies such as IVF. We are hoping other provinces are watching and learning from Ontario's lead."

Currently, four provinces provide some form of financial support to assist families seeking IVF: Ontario, Quebec,Manitoba, and New Brunswick. Quebec, which was once seen as a leader in Canada in its support of infertile patients, has dropped behind Ontario since it stopped fully funding IVF in late 2015. The ranking, however, recognizes the province still offers some financial support through its newly-implemented sliding scale tax credit for expenses related to IVF based on income level, and continued coverage of fertility drugs.

Manitoba and New Brunswick, which offer a tax credit and one-time grant to patients respectively, placed third and fourth. In recent years, some provinces without funding for fertility treatments (Alberta and British Columbia) have begun calling for the implementation of their own public funding models to assist families looking to expand their families through IVF.

Prior to the Ontario government's decision to contribute to the cost of one IVF treatment cycle, most patients faced financial barriers when it came to receiving the treatment which can cost as much as $10,000 per cycle. The province also boasts the highest number of IVF fertility clinics per million people, as listed on the Canadian Fertility and Andrology Society's website.

Conceivable Dreams believes that having a healthy number of clinics per million is an important factor for patients seeking IVF treatment, as it ensures they have some choice in where they access what can be a very personal and invasive procedure. The number of clinics can also equate to better coverage outside major urban centres. The organization believes it is no coincidence that the province with the best funding also boasts the greatest number of clinics for patients to access and choose from. 

During Canadian Infertility Awareness Week, Conceivable Dreams wants to create awareness around the growing issue of infertility which now affects one in six Canadians. It hopes that informative tools such as this ranking will help to spread the word about available opportunities and highlight the need for more publicly funded programs across the country.

"Every family should have the opportunity to grow their family and we are happy to work with partner advocacy groups across the country to encourage provinces at the bottom of this ranking to provide equitable access to IVF funding," added Xavier. "In Ontario, we will not stop advocating on behalf of families to make sure the program remains inclusive and open to feedback and individual experiences. We would also love to see more access to clinics for patients in northern Ontario, as well as more coverage for fertility drugs in the employee benefit plans."

The infographic above provides a visual representation of the current status of public funding for IVF inCanada. These rankings are based on the level of provincial funding dedicated to treatment, as well as the number of available fertility clinics per one million people.

About Conceivable Dreams 
Conceivable Dreams is a broad-based organization of patients, family members, health professionals and other supporters dedicated to achieving equitable access to funding for in vitro fertilization (IVF) for men and women facing infertility.

Aytu BioScience Demonstrates Expanded Clinical Utility of MiOXSYS™ for Assessing Oxidative Stress as a Marker for Male Infertility with New Study

ENGLEWOOD, Colo., May 10, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced new clinical findings that further validate and expand the potential utility of its MiOXSYS System as an advanced tool for assessing oxidative stress in human semen, which is broadly implicated as a major cause of male infertility. The results demonstrate that the level of oxidative stress reported by MiOXSYS from semen samples that had been frozen and thawed did not differ significantly from readings taken before freezing. This is significant, as it eliminates the need for fresh sampling and enables MiOXSYS to be used by regional or national reference laboratories that can receive and store shipped frozen samples, in addition to rapid, on-site testing by local urologists' offices, hospital, and fertility clinical laboratories.

The poster, titled, "Validation of oxidation-reduction potential in fresh and frozen semen samples with MiOXSYS™ System," was presented yesterday by the study's principal investigator, Ashok Agarwal, Ph.D., Director of the Glickman Urological & Kidney Institute's Andrology Center at Cleveland Clinic and Director of the American Center for Reproductive Medicine, at the 111th American Urological Society Annual Meeting in San Diego, CA.

Josh Disbrow, Chief Executive Officer of Aytu BioScience, stated, "These latest clinical findings add robustness to our MiOXSYS System, which we've already demonstrated to be a uniquely dynamic tool for assessing oxidative stress levels in semen as it relates to male infertility, offering substantial clinical benefit beyond the complicated and highly time-sensitive methods used today.  Being able to use MiOXSYS to analyze frozen then thawed semen samples is another key differentiator for our product that further reduces the burden and increases efficiency for routine oxidative stress testing. It also enables Aytu to potentially engage with large laboratory networks to offer MiOXSYS testing through their current frozen sample collection channels. As we continue to pursue FDA clearance of MiOXSYS in the U.S. by conducting larger, multicenter studies, these commercial implications may add significantly greater value to the product upon potential launch."

In the study, semen samples were collected from 20 healthy normospermic men and oxidative stress was induced using varying concentrations of cumene hydroperoxide (CH). Using MiOXSYS, the differences in oxidative stress readings between pre-freeze and post-thaw samples were not significant, either for controls or samples exposed to CH, indicating that MiOXSYS can measure real-time oxidative stress levels accurately in both fresh and frozen semen samples. Furthermore, MiOXSYS was sensitive enough to detect CH-induced changes when compared with control (Mean ± standard error of mean) in oxidative stress as measured by static ORP (millivolts (mV)/106 sperm/mL) both prior to freezing (0.52 + 0.24; 95 % confidence interval (0.03, 1.01); p=0.04) and after post-thaw change (0.75 + 0.31; 95 % confidence interval (0.10, 1.39); p=.025), as an indicator of strong test performance under both conditions. There was also a dose-dependent decrease in sperm motility in samples upon exposure to CH, confirming a decline in sperm quality as a result of oxidative stress. 

The MiOXSYS System received CE Marking in the European Union in January 2016 and approval from Health Canada in March 2016, and it is currently being commercialized in Europe and the Middle East. Aytu has established and will continue to seek additional partnerships with prominent hospitals, academic centers, and other early MiOXSYS users in order to develop these markets.

About Aytu BioScience, Inc. 
Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on global commercialization of novel products in the field of urology. The company currently markets two products: ProstaScint® (capromab pendetide), the only FDA-approved imaging agent specific to prostate cancer, and Primsol® (trimethoprim hydrochloride), the only FDA-approved trimethoprim-only oral solution for urinary tract infections. Aytu recently acquired exclusive U.S. rights to Natesto®, the first and only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"), which the company plans to launch in July 2016. Additionally, Aytu is developing MiOXSYS™, a novel, rapid semen analysis system with the potential to become a standard of care for the diagnosis and management of male infertility caused by oxidative stress. MiOXSYS is commercialized outside the U.S. where it is a CE Marked, Health Canada cleared product, and Aytu is conducting U.S.-based clinical trials in pursuit of 510k de novo medical device clearance by the FDA. Aytu's strategy is to continue building its portfolio of revenue-generating urology products, leveraging its focused commercial team and expertise to build leading brands within well-established markets.

Investors & Media: 
Tiberend Strategic Advisors, Inc. 
Joshua Drumm, Ph.D.:; (212) 375-2664  
Janine McCargo:; (646) 604-5150

Forward Looking Statement 
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, including statements regarding our anticipated future clinical and regulatory events, future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. Forward looking statements are generally written in the future tense and/or are preceded by words such as "may," "will," "should," "forecast," "could," "expect," "suggest," "believe," "estimate," "continue," "anticipate," "intend," "plan," or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: risks related to our planned launch and commercialization of Natesto and the integration of Natesto into our existing operations; our plans for product growth, expansion and acquisition; the anticipated start dates, durations and completion dates, as well as the potential future results, of our ongoing and future clinical trials; risks relating to gaining market acceptance of our products; obtaining reimbursement by third-party payors; the potential future commercialization of our product candidates; the anticipated designs of our future clinical trials; anticipated future regulatory submissions and events; our anticipated future cash position; and future events under our current and potential future collaborations. We also refer you to the risks described in "Risk Factors" in Part I, Item 1A of Aytu BioScience, Inc.'s Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time.


SOURCE Aytu BioScience, Inc.

12th Edition of the EMD Serono Specialty Digest™ Now Available

Scott Filosi, Senior Vice President, Market Access & Customer Solutions, EMD Serono

Scott Filosi, Senior Vice President, Market Access & Customer Solutions, EMD Serono

Value of specialty medicines, appropriate clinical use identified as critical managed care challenges

ROCKLAND, Mass., May 9, 2016 /PRNewswire/ -- EMD Serono, the North America biopharmaceutical business of Merck KGaA, Darmstadt, Germany, announced the release of the 12th edition of the EMD Serono Specialty Digest™.  The Digest, which was featured last week at the Asembia Specialty Pharmacy Summit in Las Vegas, NV,  is an industry resource that provides market data on health plans' management of specialty pharmaceuticals in 2015 and identifies common trends occurring across plans. The Digest is available to those who request a copy at

"EMD Serono has a longstanding commitment to customers and patients to further the understanding of trends in the management of specialty pharmaceuticals and ultimately, improve patient outcomes," said Scott Filosi, Senior Vice President, Market Access & Customer Solutions, EMD Serono. "It is our hope that this year's Digest findings will help spur conversations around ways to ensure continued patient access to optimal care." 

The 12th edition of the EMD Serono Specialty Digest includes data from 58 commercial health plans across the country, representing more than 140 million covered lives. New to the Digest this year is an oncology-specific supplement that includes a deeper analysis into the therapeutic category, which continues to be a major focus for health plans.  The new oncology-specific supplement is scheduled to be available in June.

"The findings in the area of oncology shed light on new trends such as the adoption of clinical pathways as well as concerns around restricting product use and the cost of infusion site visits for payers," said Kevin Host, President, Artemetrx, who oversaw the development of this year's Digest. "Understanding these managed care challenges as they relate to oncology is an important step in better meeting the needs of patients."

Further findings from this year's Digest show that while alignment of pharmacy and medical benefits has improved, it still remains a major issue for some plans. Additionally, plans are more likely to select preferred products and to exclude non-preferred agents as a therapy class matures post-launch. 

The EMD Serono Specialty Digest was first developed in 2004 to provide a comprehensive reference for managed care decision makers regarding the management of specialty products. Over the past twelve years, health plans, Pharmacy Benefit Managers (PBMs), employers, specialty pharmacies, and pharmaceutical companies have relied on the Digest to identify current and future trends in the management of specialty pharmaceuticals.

About EMD Serono, Inc. 
EMD Serono is the North America biopharma business of Merck KGaA, Darmstadt, Germany - a leading science and technology company - focused exclusively on specialty care. For more than 40 years, the business has integrated cutting-edge science, innovative products and industry-leading patient support and access programs. EMD Serono has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in oncology, immuno-oncology and immunology as R&D focus areas. Today, the business has more than 1,100 employees around the country with commercial, clinical and research operations based in the company's home state of Massachusetts.

About Merck KGaA, Darmstadt, Germany
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck KGaA, Darmstadt, Germany, generated sales of € 12.8 billion in 66 countries.

Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the Merck KGaA, Darmstadt, Germany, name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Your Contact
Melissa Manganello 1-781-681-2393

Photo -



IVF Market Size Projected to Reach USD 27 Billion by 2022: Grand View Research, Inc

SAN FRANCISCO, May 3, 2016 /PRNewswire/ --

Global In-Vitro Fertilization (IVF) market is expected to reach USD 27 billion by 2022, according to a new report by Grand View Research, Inc. The market is driven by the increasing incidence of infertility owing to, lifestyle changes, expansion of fertility procedures for treating male infertility such as ICSI, government initiatives to provide better reimbursement policies, and continuous efforts by the industry contributors. 

     (Logo: )

Moreover, the availability of genomic testing enabling the prevention of the transfer of genetic disease during IVF use is further expected to drive the market demand. The increase in the number of IVF treatment has led more insurance players to cover the IVF procedures. This has ultimately led to competitive pricing and has moderated the treatment costs as IVF has been a successfully practiced technology. This will most likely drive the market by introducing treatment standardization and automation. 

The behavioral shift in the society is a major factor contributing to the decreased Total Fertility Rate (TFR). These factors include an increasing number of women in the labor force, the increased age of the first birth, a shift from rural to urban societies, lower marriage rates, postponement of marriage, and greater levels of education for women. 

Obesity is another factor, which has led to an increase in infertility in the population. This is due to the fact that the fat deposited on women's abdomen prevents follicular stimulation and produces male hormones. In the case of males, the rising fat decreases testosterone levels causing a problem in sperm production. Doctors have started recommending weight loss in men prior to fertility treatments along with proper Body Mass Index (BMI) maintenance. The U.S. Endocrine Society has established the use of Letrozole to increase the testosterone levels in obese patients. 

Browse full research report with TOC on "In-Vitro Fertilization (IVF) Market Analysis by Procedures (Intracytoplasmic Sperm Injection (ICSI), Frozen Embryo Replacement (FER), Pre-implantation Genetic Diagnosis (PGD)), By Types of Cycles (Fresh Donor, Frozen Donor, Fresh Non-donor, Frozen Non-donor), By Instruments (IVD Disposable Devices, Culture Media, Capital Equipment), And Segment Forecasts to 2022" at:

Further key findings from the report suggest:  

  • Intracytoplasmic Sperm Injection (ICSI) dominated the market in 2014.ICSI was introduced in the year 1992 and boosted the fertility rates from 50% to 80%, according to the American Society for Reproductive Medicine. In April 2016, Nigeria recorded its first successful delivery from a frozen egg. Bridge Clinic has stored the eggs using the flash-freezing technique. With this birth, Nigeria has put itself on the global map as it now offers IVF through frozen eggs. The eggs were then fertilized using the ICSI technique. 
  • Frozen Embryo Replacement (FER) technique is expected to witness a rapid rise in demand. Conventionally, most embryos were transferred through fresh cycles. However, with technology refinement, the number of frozen embryo transfers and the success rates have increased. Moreover, the policy of freezing the embryos has also reduced the chances of ovarian hyper-stimulation. The frozen embryo transfers enable single egg transfer, thus, giving enough time for the endometrial layer to heal from the medicine stimulation effect. This ensures higher success rates. 
  • Culture media dominated the overall market in terms of revenue in 2014. With the increasing government funding and industrial support for employees for egg/sperm freezing, the demand for cryopreservation and the needed media for it is expected to witness growth. There has been an increase in the research activities undertaken to improve the culture media and to procure maximum boar sperms or eggs, spurring market growth. Moreover, the increasing number of egg/sperm donor banks is expected to drive the demand for sperm, egg, and embryo processing media during the forecast period. 
  • Europe dominated the IVF market in 2014. High quality of treatment offered at the most economical price, and the adherence to medical standards have contributed to its market leadership. In Europe, the NHS covers three IVF cycles and has also started providing coverage for gametes freezing. Moreover, the region is an attraction for international clients as countries, such as Spain, have the highest number of egg donors. The clinics also provide sex identification and other IVF treatments, which are not offered in North America. 
  • North America also accounted for a significant share of the market in 2014. The standardization of procedures through automation, regulatory reforms, government funding for egg/sperm storage, and industry players introducing more IVF treatments are some contributing factors for North Americadominating the IVF market. 
  • The presence of favorable reimbursement framework (implementation of USD 50 million 5-year plans by the U.S Department of Defense for sperm/egg freezing coverage) is also expected to drive regional market growth over the next six years. The increasing number of clinics undertaking newer industrial techniques to offer better fertility success rates is also expected to boost the regional market demand. 
  • The demand for IVF treatment is expected to boom in APAC owing to fertility tourism, increasing foreign industries trying to penetrate the economically developing countries and the changing regulatory landscape. 
  • The Asia Pacific Initiative on Reproduction (ASPIRE), the task force of clinicians and scientists is involved in the monitoring and management of fertility and Assisted Reproductive Technology (ART). Such initiatives promote awareness levels thereby, driving growth. 
  • Industry contributors are introducing newer automation to shift the IVF treatment from invasive to a minimally invasive or non-invasive procedure. The industry players are also trying technologies, which can enable older women to have enhanced fertility rates. For instance, in August 2015, OvaScience announced the results of its first published analysis comparing AUGMENT fertility treatment with a standard IVF. The results showed a significantly higher rate of selection and transfer of embryos as compared to the standard treatment. 
  • Some key players in this market includeEMD Serono Inc., Boston IVF, OvaScience, Thermo Fisher Scientific Inc., Vitrolife AB, Irvine Scientific, CooperSurgical, Inc., Cook Medical Inc., Genea Biomedx and Progyny Inc. 

Grand View Research has segmented the In-Vitro Fertilization (IVF) market on the basis of procedures, type of cycles, instruments, end-use, and regions:  

  • Global In-Vitro Fertilization (IVF) Procedures Outlook (Revenue, USD Million, 2012 - 2022) 
    • Intracytoplasmic Sperm Injection (ICSI)
    • Frozen Embryo Replacement (FER)
    • Pre-implantation Genetic Diagnosis (PGD)
    • Others
  • Global In-Vitro Fertilization (IVF) Types of Cycles Outlook (Revenue, USD Million, 2012 - 2022) 
    • Fresh Donor
    • Frozen Donor
    • Fresh Non-donor
    • Frozen Non-donor
  • Global In-Vitro Fertilization (IVF) Instruments Outlook (Revenue, USD Million, 2012 - 2022) 
    • IVD Disposable Devices
    • Culture Media
    • Capital Equipment
  • In-Vitro Fertilization (IVF) Regional Outlook (Revenue, USD Million, 2012 - 2022) 
    • North America
      • U.S.
      • Canada
    • Europe
      • UK
      • Germany
      • France
      • Rest of Europe
    • Asia Pacific
      • India
      • Japan
      • China
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • MEA
      • South Africa
      • Rest of MEA 



Dr. Hyacinth Nicole Browne Joins Hudson Valley Fertility

FISHKILL, N.Y., April 28, 2016 /PRNewswire-USNewswire/ -- Hudson Valley Fertility, a leading infertility and reproductive health practice in the Hudson Valley of New York State, is pleased to announce that Dr. Hyacinth Nicole Browne will join the practice. Dr. Browne will see patients at their new office at 380 Route 202 in Somers. The new office will help improve access to reproductive care in Westchester, Putnam and Western Connecticut.

Dr. Browne graduated with honors from Dartmouth College and completed medical school at Yale University. She completed a residency in Obstetrics and Gynecology at the Yale New Haven Hospital, followed by fellowship in Reproductive Endocrinology and Infertility at the National Institutes of Health. Prior to joining Hudson Valley Fertility, Dr Browne served as Medical Director of a private IVF and reproductive practice. She has years of experience in reproductive medicine, and is the recipient of numerous scientific and clinical awards. She also has been noted to have excellent online patient reviews, as a testament to the compassionate and personalized medical care that she gives to her patients.   

According to Dr. Daniel Levine, Medical Director of Hudson Valley Fertility, "We are thrilled to have Dr. Browne become part of our family.  Dr. Browne brings a wealth of knowledge, experience, compassion and sensitivity to the practice of reproductive medicine. She will be a key part of our mission to help couples struggling with infertility to achieve their dream of having a child and building a family."

Hudson Valley Fertility, with offices in Fishkill and Somers, is the only medical practice in the region offering comprehensive, advanced infertility treatment and reproductive health services, as well as educational and support services for patients.  Hudson Valley Fertility specializes in the diagnosis and treatment of infertility and reproductive disorders, and offers a full range of treatment options, from simple drug therapies to In-Vitro Fertilization (IVF) and Assisted Reproductive Technologies. The practice offers the highest standards of personalized and affordable reproductive care for Dutchess, Putnam, Ulster, Rockland, Westchester, Orange, and Sullivan counties as well as Western Connecticut, Northern New Jersey and Pennsylvania.



A new way to track ovulation at home

MFB Fertility, LLC Develops Only In-Home Test to Detect Progesterone


Research has shown that couples get pregnant faster when they know when exactly when ovulation takes place. Fertility monitors and ovulation predictor kits allow couples to track estrogen and luteinizing hormone (LH) levels from home. However, until now, there were no tests available to track progesterone.



Erie, CO, March 23, 2016 --( The process of ovulation involves three main hormones that change during the monthly menstrual cycle. The first is estrogen, this hormone is essential for an egg to mature. Second is luteinizing hormone (LH). A surge in this hormone allows the egg to mature and be released from the ovary (also known as ovulation). Finally, there is progesterone. This hormone is produced in the ovary after the mature egg is released and acts to prepare the uterus for embryo implantation. If pregnancy occurs, progesterone levels will remain high throughout the pregnancy to help support fetal growth. Fertility monitors and ovulation predictor kits allow couples to track estrogen and LH levels from home. However, until now, there were no tests available to track progesterone. MFB Fertility, LLC has developed a test that measures the presence of progesterone in urine, which helps a woman "double check" that they have ovulated. Read more at or click here 

New Study: IVF success rates can be excellent for high responding women when using a Lupron trigger

Infertility Specialist Richard Sherbahn Presents New Research Study at the American Society for Reproductive Medicine Annual Meeting

Results of a new research study, conducted by Dr. Sherbahn and Dr. Catenacci of Advanced Fertility Center of Chicago, show that proper use of a Lupron trigger can result in high IVF success rates, and no ovarian hyperstimulation.

"IVF success rates can be excellent for high responding women when using a Lupron trigger."

Press Release: Gurnee, IL (PRWEB) January 15, 2015 --- Dr. Sherbahn's Professional Member profile and  Biography

Board-certified fertility specialist Richard Sherbahn, MD recently presented research on the use of a Lupron trigger (agonist trigger) to prevent ovarian hyperstimulation in women with a high response to ovarian stimulation for IVF at the annual meeting of the American Society for Reproductive Medicine in Honolulu, Hawaii. The study, conducted by Dr. Sherbahn and Dr. Catenacci of Advanced Fertility Center of Chicago, looked at IVF live birth success rates, pregnancy loss rates, and ovarian hyperstimulation syndrome (OHSS) occurrence rates in high responders that had a pure Lupron trigger vs. a dual trigger with Lupron and a small dose of HCG.

Included in the study were 135 women under the age of 38, all using their own eggs for in-vitro fertilization (IVF). They each either received a pure Lupron trigger or a Lupron trigger plus a small dose of HCG (1500-2000 units), between November 2011 and July 2013. Patients were separated into 2 groups based on their trigger injections (pure agonist trigger vs dual trigger). Intensive support was given in the luteal phase using intramuscular progesterone and oral or transdermal estradiol.

The mean number of eggs retrieved, miscarriage rates, and the rate of development of ovarian hyperstimulation syndrome were not significantly different between the pure Lupron trigger group and the dual trigger group. The live birth rate per egg retrieval was 52.6% in the pure agonist trigger group, while the dual trigger group rate was 64.4%. The difference was not statistically significant. There was a trend for higher pregnancy loss rates in the pure agonist group, but it was not statistically significant either.

The pure Lupron trigger group was then split into 2 groups according to the peak estradiol level - under or over 4000 pg/ml. The IVF live birth rate was significantly higher (p<0.05) in the group with peak estradiol levels greater than 4000 pg/ml (42.2% vs. 67.7%).

“Published studies on Lupron triggers, and other agonist drug triggers, have shown inconsistent results. We believe that, in the studies with poor IVF success rates, the patients were not given enough estrogen and progesterone support in the luteal phase and early pregnancy. We believe the luteal support needs to be aggressive, and must be continued into early pregnancy, until the placenta makes enough hormones to support the pregnancy,” explained Dr. Sherbahn.

The results of the study showed that live birth rates with IVF, using a pure agonist trigger, can be very high when intensive luteal support is given. Also, success rates using a pure Lupron trigger are significantly higher when the peak estradiol level is above 4000 pg/ml. Therefore, if the peak estradiol level is below 4000 pg/ml, a dual trigger with a low dose of 1500 IU of HCG should be considered.

“We believe that the Lupron trigger is a vital tool that has been available to IVF doctors for the last several years for reducing the occurrence of ovarian hyperstimulation – particularly in women with polycystic ovarian syndrome, PCOS. Before the Lupron trigger was available, there were significantly more cases of ovarian hyperstimulation syndrome, which is always uncomfortable for the woman, and in rare cases can result in severe medical complications,” said Sherbahn. Proper use of pure agonist triggers can result in excellent IVF success rates, and no ovarian hyperstimulation, or rare hyperstimulation cases with a dual trigger.

About The Advanced Fertility Center of Chicago

The Advanced Fertility Center of Chicago, with offices in Gurnee and Crystal Lake, Ill., offers advanced reproductive technology services such as in-vitro fertilization (IVF), intracytoplasmic sperm injection, preimplantation genetic diagnosis, egg freezing and egg donation.

The Center specializes in individualized care, and has IVF success rates and egg donation success rates that are well above national averages.

The Center’s web site,, offers more than 300 articles on fertility issues and IVF. To schedule an appointment, call 847.662.1818.